Business
The BARD1 (ASX:BD1) share price eyes record highs after positive research results
The BARD1 Life Sciences (ASX: BD1) share price is on watch today after positive results from the evaluation of its EXO-NET product in pancreatic cancer.
Let’s take a closer look at the announcement and what this means for the BARD1 share price.
What’s driving the BARD1 share price higher?
BARD1 maintains a cancer diagnostics portfolio. This includes the commercialised hTRET test which is used as a supplement to urine cytology tests. Additionally, the portfolio also includes diagnostics tests in development for ovarian, breast, lung, prostate, and pancreatic cancers. The group is working towards commercialising its…
-
General18 hours agoByford rail extension opening marks final stage of Perth Metronet
-
Noosa News23 hours agoFatal traffic crash, Baringa – Sunshine Coast
-
General19 hours agoMango the muster cat draws attention to western Queensland’s ongoing recovery
-
Business21 hours agoWhat $10,000 invested in the iShares S&P 500 IVV ETF could be in 10 years